Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation-Reference-Cited by-同舟云学术

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation

Published:2022-12 Issue:12 Volume:22 Page:1666-1668
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Wang Qian,Li Zhiteng,Ho Jerren,Guo Yicheng,Yeh Andre Yanchen,Mohri Hiroshi,Liu Michael,Wang Maple,Yu Jian,Shah Jayesh G,Chang Jennifer Y,Herbas Favio,Yin Michael T,Sobieszczyk Magdalena E,Sheng Zizhang,Liu Lihong,Ho David D

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference3 articles.

1. GISAID: Global initiative on sharing all influenza data - from vision to reality;Shu;Euro Surveill,2017

2. Striking antibody evasion manifested by the omicron variant of SARS-CoV-2;Liu;Nature,2022

3. Antibody evasion by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4 and BA.5;Wang;Nature,2022

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness;Frontiers in Public Health;2024-08-15

2. An update on the anti-spike monoclonal antibody pipeline for SARS-CoV-2;Clinical Microbiology and Infection;2024-08

3. AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults;Science Translational Medicine;2024-06-26

4. Recurrent SARS-CoV-2 spike mutations confer growth advantages to select JN.1 sublineages;2024-05-29

5. Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials;Infectious Diseases and Therapy;2024-05-04